Send me a link:

*Text messaging rates may apply.

 Dow Down0.72% Nasdaq Down0.50%

Array BioPharma, Inc. (ARRY)

-NasdaqGM
4.18 Down 0.10(2.34%) Jul 25, 3:59PM EDT
ProfileGet Profile for:
Array BioPharma, Inc.
3200 Walnut Street
Boulder, CO 80301
United States - Map
Phone: 303-381-6600
Fax: 303-449-5376
Website: http://www.arraybiopharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:265

Business Summary 

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company’s partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs; and Biogen Idec for the discovery and development of inhibitors to treat autoimmune disorders. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Array BioPharma, Inc.

Corporate Governance 
Array BioPharma, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Ron Squarer BSc (Biochemistry), MBA, 47
Chief Exec. Officer and Director
1.10M0.00
Mr. David L. Snitman Ph.D., 62
Co-Founder, Chief Operating Officer and VP of Bus. Devel.
579.00K0.00
Mr. R. Michael Carruthers , 56
Chief Financial Officer and Principal Accounting Officer
527.00K0.00
Dr. Michael N. Needle M.D., 54
Chief Medical Officer
226.00K0.00
Dr. Nicholas A. Saccamano Ph.D.,
Chief Scientific Officer
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders